Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
about
Scalable rule-based modelling of allosteric proteins and biochemical networksTherapeutic potential for novel drugs targeting the type 1 cholecystokinin receptorSignal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonistPhysiology of the orexinergic/hypocretinergic system: a revisit in 2012Biased and g protein-independent signaling of chemokine receptorsGaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessorsRecent advances in understanding the extracellular calcium-sensing receptorNicotinic acid receptor agonists differentially activate downstream effectorsSignalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalphaG(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtypeRNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificityAgonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cellsHigh-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist actionNiacin stimulates adiponectin secretion through the GPR109A receptorG-protein oestrogen receptor 1: trials and tribulations of a membrane oestrogen receptorA simple method for quantifying functional selectivity and agonist biasLSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.Agonist-selective signaling of G protein-coupled receptor: mechanisms and implicationsGenetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.Teaching old receptors new tricks: biasing seven-transmembrane receptors.Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Ligand-induced modulation of the free-energy landscape of G protein-coupled receptors explored by adaptive biasing techniquesOdorant-specific modes of signaling in mammalian olfaction.The year in G protein-coupled receptor research.The GPCR membrane receptor, DopEcR, mediates the actions of both dopamine and ecdysone to control sex pheromone perception in an insectPlasmon resonance studies of agonist/antagonist binding to the human delta-opioid receptor: new structural insights into receptor-ligand interactions.The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.Neurokinin B and the hypothalamic regulation of reproduction.Defect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene.Identification of novel functionally selective κ-opioid receptor scaffolds.Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivoThe potential for selective pharmacological therapies through biased receptor signalingFitting the complexity of GPCRs modulation into simple hypotheses of ligand design.Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists.A Pluridimensional View of Biased Agonism.Exploring a role for heteromerization in GPCR signalling specificity.Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity.
P2860
Q21145330-8DCED433-4BD5-4FCD-8676-999F0F1FFE1DQ24628602-BD84CF88-705F-4D68-8CF3-6735A9E031D4Q24644854-3360AFA3-2830-4B1C-8562-FBEE63D78BD2Q26822470-1C2E2C4F-8BAD-4E3B-A45D-BA95A60A04ACQ26823970-7CEBB251-A4DB-4807-932C-CB042D9C13E5Q27005640-01623ECA-6674-4602-9B36-B870EE74AD17Q28069545-0499BC62-9506-4F4D-8153-4B90D984989DQ28298974-1C0AE76D-E044-4F5A-84E9-6499F3C3306CQ28343257-7A8AB8A6-499B-4EBA-9442-C0111107756AQ28350001-F1C6F5E6-BBD9-4364-A3B8-9B7F5374754BQ28359232-4552963F-26CA-427E-B17F-466431D58DFFQ28361199-A3EC9DC3-6152-4770-B3D7-46129A6EA309Q28374171-81B41FE0-C92D-4904-B96F-B46AA19BF896Q28575089-2C218648-F065-4145-A9BA-BAE907B48136Q28576185-97A11FC6-3436-4079-95F1-AD2B81F974C0Q28728741-754C8952-45F3-40EE-8DE6-9321FA201739Q30484494-FFC033C8-CDB7-4AA1-B053-C30A94B7E1C2Q33604101-37C93D68-2DF7-42D9-BD1C-E56B2B688F44Q33714695-9942216C-3123-44D8-80AC-569E77145130Q33890786-24C88E0B-52A3-4AE7-A0E3-174CCA13AAF1Q33966353-460C6060-B624-4DBE-8C6F-EB99D05716ABQ33985759-9C3FBE13-4ACC-4CDD-8F7D-5E83E086F292Q34011162-DD4F486A-EB69-4805-8300-94D7444B26CAQ34055218-B46EBA24-757D-41FE-B1C6-3AA5B6D45B97Q34075509-1C301F11-8297-45FC-8A4F-6A5801F50238Q34088801-E73F7FB1-E3DA-4E8F-81E2-F9CBEC5759F3Q34171396-C2DF983C-E387-4946-A551-9A927FC510C7Q34174259-B65AB005-0944-40E2-9703-D6C17708B2DEQ34245210-3D69D32B-80D6-4877-82C7-00B8A874D546Q34284419-D523EBF4-73C8-4D96-91F8-A8907456F53EQ34354034-6B742891-96D7-4CB1-B8EF-DC7AC241F2CDQ34365195-9AAD368C-2C4A-484D-9547-7FAB6AAD6F45Q34376764-6D59354D-8970-434F-BD4E-1D3A0572E01DQ34402623-0F8293F9-DDB3-434B-96BD-948E55683480Q34402658-EA3BFCB1-93FB-47C8-BB1E-F75F41D88C59Q34451544-9BE9F3CB-A95B-41F7-8A52-E35F3E44EBB0Q34506086-2304F902-AC62-46D8-BA76-99F707749A37Q34540545-BF777281-89B6-4866-934F-04A2C638D153Q34660378-4064F8C8-8B2D-4320-817C-5AAA61B4AC55Q34760546-98DD2B53-6C6B-4E53-808B-783EAA4D0755
P2860
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@ast
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@en
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@nl
type
label
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@ast
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@en
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@nl
prefLabel
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@ast
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@en
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@nl
P1476
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
@en
P2093
P304
P356
10.1016/S0165-6147(00)89032-X
P577
1995-07-01T00:00:00Z